Eli Lilly and Company
893 S Delaware St
Indianapolis
Indiana
46285
United States
2830 articles with Eli Lilly and Company
-
Lilly Announces Webcast to Provide Diabetes Portfolio Update at ADA
6/11/2021
Eli Lilly and Company (NYSE: LLY) will host a webcast on Thursday, July 1, 2021 to discuss the company's diabetes portfolio and its presentations at the American Diabetes Association's Virtual 81st Scientific Sessions.
-
This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.
-
ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer
6/10/2021
ALX Oncology announced it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company to evaluate the combination of ALX148, a next generation CD47 blocker, and CYRAMZA®, Lilly’s anti-VEGFR2 antibody, for the treatment of patients with HER2-positive gastric cancer or gastroesophageal junction cancer.
-
Strateos Closes $56 Million Series B Financing to Accelerate the Roll-Out of its SmartLab of the Future Platform
6/8/2021
New financing led by DCVC and Lux Capital, will expand the next generation of smart lab solutions with direct access to automation to accelerate discovery in the life sciences
-
Despite controversy over the drug’s effectiveness, it appears to have spiked interest in investing in Alzheimer’s drug companies, something that had been on the decline for several years.
-
Lilly Announces New Clinical Data from Verzenio and Oral SERD Programs at the American Society of Clinical Oncology Annual Meeting
6/4/2021
Eli Lilly and Company (NYSE: LLY) today announced new data for the investigational use of Verzenio® (abemaciclib) in high risk early breast cancer, and for its oral selective estrogen receptor degrader (SERD) LY3484356 at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO).
-
REGEN-COV's 1,200 mg dose is authorized to treat mild-to-moderate COVID-19 in adults and children 12 years and older who weigh 40 kilograms or more.
-
Innovent and Lilly Jointly Announce the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Squamous Non-Small Cell Lung Cancer
6/3/2021
Innovent Biologics, Inc. and Eli Lilly and Company jointly announced that the National Medical Products Administration of China has approved the supplemental New Drug Application for TYVYT® in combination with gemcitabine and platinum chemotherapy as first-line therapy for people with unresectable locally advanced or metastatic squamous non-small cell lung cancer.
-
Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly's Preventive and Acute Treatment Portfolio at AHS 2021
6/3/2021
- Nearly half of people with migraine hesitated to seek care, choosing self-management and out of concern their disease would not be taken seriously, based on new findings from OVERCOME (U.S.), the largest population-based study of its kind
-
Lilly to Participate in Goldman Sachs Healthcare Conference - June 03, 2021
6/3/2021
Eli Lilly and Company will participate in the Goldman Sachs Healthcare Conference on June 9 and 10, 2021.
-
OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses
6/1/2021
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present data from post-hoc analyses that suggested OLUMIANT® (baricitinib) 4 mg tablet reduced pain and duration of morning joint stiffness, and improved overall physical function at 12 weeks, among patients with moderate to severe rheumatoid arthritis (RA), compared to HUMIRA®
-
The EUA was granted base on interim data from the Phase III COMET-ICE trial in high-risk adult outpatients.
-
This is the second IND to come out of the two companies’ collaboration. They will initiate a Phase I trial of the drug in cardiometabolic diseases.
-
Lilly said it is cooperating fully with the DOJ and is in the process of conducting its own investigation into the allegations made against the company.
-
Wang, who has played a key role in the development of more than 25 innovative medicines at Eli Lilly and GlaxoSmithKline, made him the ideal fit for the company’s next chapter.
-
Mirikizumab Improves Fatigue in Patients with Crohn's Disease in Phase 2 Trial
5/22/2021
In a pre-specified analysis of the Phase 2 SERENITY study, Eli Lilly and Company's mirikizumab improved fatigue in patients with moderately to severely active Crohn's disease at 12 weeks, as measured by the mean change in FACIT-Fatigue scores compared to placebo, with improvements that were sustained up to one year.
-
Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial
5/20/2021
SURPASS program has now met regulatory submission requirements for evaluating cardiovascular risk; Lilly intends to submit registration package to regulatory authorities by the end of 2021
-
Eli Lilly's SURPASS-4 trial program shows tirzepatide, significantly reduced blood glucose levels and body weight better than insulin glargine in adult patients with type 2 diabetes.
-
Arecor Announces an Exclusive Formulation Study Collaboration With Lilly
5/20/2021
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a formulation study partnership with Eli Lilly and Company.
-
Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
5/19/2021
New data from across Eli Lilly and Company's oncology portfolio will be presented at the 2021 American Society of Clinical Oncology Annual Meeting, held June 4-8, 2021.